Learn About Vasculitis

What is the definition of Vasculitis?
Vasculitis is considered to be an autoimmune disease wherein the immune system causes inflammation of the blood vessels. The disease can be acute or chronic. There are many types of vasculitis, which mainly occurs in rare diseases. Vasculitis causes changes in blood vessels which decrease blood flow and oxygen to body tissues and vital organs. While the causes of vasculitis are often unknown, it can occur after an infection, another disease, or a reaction to medication when the immune system is triggered and attacks the vascular system. Genetics may also be a factor.
Save information for later
Sign Up
What are the symptoms of Vasculitis?
Signs and symptoms of vasculitis can vary but include red spots, lumps, or sores on the skin, rash, nerve problems (which may cause numbness or weakness in hands and feet), cough and difficulty breathing, fever, weight loss, and fatigue.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Vasculitis?
The treatment depends on the type of vasculitis, with the goal of stopping the inflammation. While some vasculitis may improve without treatment, some types require steroids, immunosuppressive drugs such as cyclophosphamide, methotrexate, azathioprine, newer drugs such as rituximab, or surgery.
Who are the top Vasculitis Local Doctors?
Learn about our expert tiers
Learn more
What are the latest Vasculitis Clinical Trials?
A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis

Summary: The primary purpose of this study is to evaluate the efficacy of guselkumab compared to placebo, in combination with a 26-week glucocorticoid (GC) taper regimen, in adult participants with new-onset or relapsing giant cell arteritis (GCA).

Match to trials
Find the right clinical trials for you in under a minute
Get started
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica

Summary: Polymyalgia rheumatica (PMR) is prevalent among elderly. Untreated, it leads to major reduction in quality of life. Glucocorticoids are the cornerstone of treatment, but have drawbacks, warranting glucocorticoid sparing treatment. A proof of concept study on Rituximab (RTX) vs placebo showed efficacy in 48 vs 21%(p=0.049) in glucocorticoid free remission after 21 weeks (Marsman et al. 2021). Thoug...

What are the Latest Advances for Vasculitis?
A chronic EBV infection causing persistent facial erythema multiforme and a retrospective literature review: A case report.
Acute cortical blindness caused by neuropsychiatric systemic lupus erythematosus.
Tired of the same old research?
Check Latest Advances
Treatment of thrombosis in KD Patients using tissue plasminogen activator: a single center study.